Informations: Ceci n’est pas la version la plus récente du modèle de données. Vous trouverez un aperçu de la version à gauche, sous Versions. Vous trouverez la version la plus actuelle ici.
Informations:
Erreur:
ID
18321
Description
A Study Of Nasopharyngeal Carcinoma (NPC) Treated With Celecoxib And ZD1839; ODM derived from: https://clinicaltrials.gov/show/NCT00212108
Lien
https://clinicaltrials.gov/show/NCT00212108
Mots-clés
Versions (2)
- 31/10/2016 31/10/2016 -
- 31/10/2016 31/10/2016 -
Téléchargé le
31 octobre 2016
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY-NC 3.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Eligibility Nasopharyngeal Carcinoma NCT00212108
Eligibility Nasopharyngeal Carcinoma NCT00212108
- StudyEvent: Eligibility
Similar models
Eligibility Nasopharyngeal Carcinoma NCT00212108
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Nasopharyngeal carcinoma
Item
1. histologically proven npc.
boolean
C2931822 (UMLS CUI [1])
Nasopharyngeal carcinoma | TNM clinical staging
Item
2. any clinical stage npc as defined by the ajcc/uicc system.
boolean
C2931822 (UMLS CUI [1])
C3258246 (UMLS CUI [2])
C3258246 (UMLS CUI [2])
Therapeutic radiology procedure | Chemoradiotherapy | Immunotherapy | Investigational New Drugs
Item
3. no prior radiotherapy, chemoradiotherapy, immunotherapy or investigational agents.
boolean
C1522449 (UMLS CUI [1])
C0436307 (UMLS CUI [2])
C0021083 (UMLS CUI [3])
C0013230 (UMLS CUI [4])
C0436307 (UMLS CUI [2])
C0021083 (UMLS CUI [3])
C0013230 (UMLS CUI [4])
Anti-Inflammatory Agents, Non-Steroidal | Adrenal Cortex Hormones
Item
4. no prior nsaids or corticosteroids for at least 4 weeks.
boolean
C0003211 (UMLS CUI [1])
C0001617 (UMLS CUI [2])
C0001617 (UMLS CUI [2])
ECOG performance status
Item
5. ecog performance status ≤ 2.
boolean
C1520224 (UMLS CUI [1])
organ function
Item
6. adequate end organ function
boolean
C0678852 (UMLS CUI [1])
Life Expectancy
Item
7. life expectancy > 3 months.
boolean
C0023671 (UMLS CUI [1])
Informed Consent
Item
8. signed informed consent -
boolean
C0021430 (UMLS CUI [1])
ID.9
Item
1. inability to take celecoxib and gefitinib for the specified period of time (14 days) prior to definitive therapy.
boolean
ID.10
Item
2. tumor not visible on fibre nasopharyngoscopy for biopsy.
boolean
Peptic Ulcer
Item
3. known peptic ulcer disease.
boolean
C0030920 (UMLS CUI [1])
ID.12
Item
4. evidence of clinically active interstitial lung disease.
boolean
ID.13
Item
5. previous or concomitant malignancies with the exception of adequately treated carcinoma-in-situ of the cervix and basal or squamous cell carcinoma of the skin.
boolean
ID.14
Item
6. women who are pregnant or lactating. females with child-bearing potential must have a negative serum pregnancy test within 7 days prior to study enrolment.
boolean
Childbearing Potential Contraceptive methods Lacking
Item
7. women of childbearing potential who are not practising adequate contraception.
boolean
C3831118 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
C0332268 (UMLS CUI [1,3])
C0700589 (UMLS CUI [1,2])
C0332268 (UMLS CUI [1,3])
ID.16
Item
8. concurrent medical problems that would significantly limit compliance with the study.
boolean
ID.17
Item
9. presence of any underlying medical conditions (eg. unstable or uncompensated respiratory, cardiac, renal or hepatic disease) that in the opinion of the investigator would make the patient unsuitable for study participation.
boolean
ID.18
Item
10. known hypersensitivity to celecoxib and gefitinib or any of the excipients of the products, known sulphonamide sensitivity and allergic reaction following the ingestion of nsaids.
boolean
ID.19
Item
11. known hiv, hbv or hcv infection. -
boolean